BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

357 related articles for article (PubMed ID: 29845338)

  • 1. Establishment of adoptive cell therapy with tumor infiltrating lymphocytes for non-small cell lung cancer patients.
    Ben-Avi R; Farhi R; Ben-Nun A; Gorodner M; Greenberg E; Markel G; Schachter J; Itzhaki O; Besser MJ
    Cancer Immunol Immunother; 2018 Aug; 67(8):1221-1230. PubMed ID: 29845338
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phenotypic analysis of tumor-infiltrating lymphocytes from non-small cell lung cancer and their potential application for adoptive cell therapy.
    Ma Y; Ou J; Lin T; Chen L; Wang J; Qiao D; Lai S; Duan C; Cheng Y; Chang R; Zhang C; Wang M
    Immunopharmacol Immunotoxicol; 2020 Aug; 42(4):319-329. PubMed ID: 32419542
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Detection of oligoclonal T lymphocytes in lymph nodes draining from advanced non-small-cell lung cancer.
    Meta M; Ponte M; Guastella M; Semino C; Pietra G; Ratto GB; Melioli G
    Cancer Immunol Immunother; 1995 Apr; 40(4):235-40. PubMed ID: 7750121
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Metastatic Lung Lesions as a Preferred Resection Site for Immunotherapy With Tumor Infiltrating Lymphocytes.
    Ben-Avi R; Itzhaki O; Simansky D; Zippel D; Markel G; Ben Nun A; Schachter J; Besser MJ
    J Immunother; 2016 Jun; 39(5):218-22. PubMed ID: 27163742
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antigen-Presenting Intratumoral B Cells Affect CD4
    Bruno TC; Ebner PJ; Moore BL; Squalls OG; Waugh KA; Eruslanov EB; Singhal S; Mitchell JD; Franklin WA; Merrick DT; McCarter MD; Palmer BE; Kern JA; Slansky JE
    Cancer Immunol Res; 2017 Oct; 5(10):898-907. PubMed ID: 28848053
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A randomized trial of adoptive immunotherapy with tumor-infiltrating lymphocytes and interleukin-2 versus standard therapy in the postoperative treatment of resected nonsmall cell lung carcinoma.
    Ratto GB; Zino P; Mirabelli S; Minuti P; Aquilina R; Fantino G; Spessa E; Ponte M; Bruzzi P; Melioli G
    Cancer; 1996 Jul; 78(2):244-51. PubMed ID: 8673999
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bimodal ex vivo expansion of T cells from patients with head and neck squamous cell carcinoma: a prerequisite for adoptive cell transfer.
    Junker N; Andersen MH; Wenandy L; Dombernowsky SL; Kiss K; Sørensen CH; Therkildsen MH; Von Buchwald C; Andersen E; Straten PT; Svane IM
    Cytotherapy; 2011 Aug; 13(7):822-34. PubMed ID: 21428850
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adherent cell depletion promotes the expansion of renal cell carcinoma infiltrating T cells with optimal characteristics for adoptive transfer.
    Braun MW; Abdelhakim H; Li M; Hyter S; Pessetto Z; Koestler DC; Pathak HB; Dunavin N; Godwin AK
    J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33037114
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combined IL-2, agonistic CD3 and 4-1BB stimulation preserve clonotype hierarchy in propagated non-small cell lung cancer tumor-infiltrating lymphocytes.
    Shah P; Forget MA; Frank ML; Jiang P; Sakellariou-Thompson D; Federico L; Khairullah R; Neutzler CA; Wistuba I; Chow CB; Long Y; Fujimoto J; Lin SY; Maitra A; Negrao MV; Mitchell KG; Weissferdt A; Vaporciyan AA; Cascone T; Roth JA; Zhang J; Sepesi B; Gibbons DL; Heymach JV; Haymaker CL; McGrail DJ; Reuben A; Bernatchez C
    J Immunother Cancer; 2022 Feb; 10(2):. PubMed ID: 35110355
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterization of tumor-infiltrating lymphocytes derived from human tumors for use as adoptive immunotherapy of cancer.
    Schiltz PM; Beutel LD; Nayak SK; Dillman RO
    J Immunother; 1997 Sep; 20(5):377-86. PubMed ID: 9336745
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The implications of clinical risk factors, CAR index, and compositional changes of immune cells on hyperprogressive disease in non-small cell lung cancer patients receiving immunotherapy.
    Kim SR; Chun SH; Kim JR; Kim SY; Seo JY; Jung CK; Gil BM; Kim JO; Ko YH; Woo IS; Shim BY; Hong SH; Kang JH
    BMC Cancer; 2021 Jan; 21(1):19. PubMed ID: 33402127
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic value of tumor-infiltrating lymphocytes for patients with completely resected stage IIIA(N2) non-small cell lung cancer.
    Feng W; Li Y; Shen L; Cai XW; Zhu ZF; Chang JH; Xiang JQ; Zhang YW; Chen HQ; Fu XL
    Oncotarget; 2016 Feb; 7(6):7227-40. PubMed ID: 26811495
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adoptive immunotherapy with tumor-infiltrating lymphocytes and interleukin-2 in patients with metastatic malignant melanoma and renal cell carcinoma: a pilot study.
    Goedegebuure PS; Douville LM; Li H; Richmond GC; Schoof DD; Scavone M; Eberlein TJ
    J Clin Oncol; 1995 Aug; 13(8):1939-49. PubMed ID: 7636534
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Isolation and in vitro expansion of lymphocytes infiltrating non-small cell lung carcinoma: functional and molecular characterisation for their use in adoptive immunotherapy.
    Melioli G; Ratto G; Guastella M; Meta M; Biassoni R; Semino C; Casartelli G; Pasquetti W; Catrullo A; Moretta L
    Eur J Cancer; 1994; 30A(1):97-102. PubMed ID: 8142173
    [TBL] [Abstract][Full Text] [Related]  

  • 15. White paper on adoptive cell therapy for cancer with tumor-infiltrating lymphocytes: a report of the CTEP subcommittee on adoptive cell therapy.
    Weber J; Atkins M; Hwu P; Radvanyi L; Sznol M; Yee C;
    Clin Cancer Res; 2011 Apr; 17(7):1664-73. PubMed ID: 21325070
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Minimally invasive liver resection to obtain tumor-infiltrating lymphocytes for adoptive cell therapy in patients with metastatic melanoma.
    Alvarez-Downing MM; Inchauste SM; Dudley ME; White DE; Wunderlich JR; Rosenberg SA; Kammula US
    World J Surg Oncol; 2012 Jun; 10():113. PubMed ID: 22726267
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Characteristics of Naive-like T Cells in Tumor-infiltrating Lymphocytes From Human Lung Cancer.
    Sheng SY; Gu Y; Lu CG; Tang YY; Zou JY; Zhang YQ; Wang RF; Hong H
    J Immunother; 2017 Jan; 40(1):1-10. PubMed ID: 27828929
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tumor-infiltrating lymphocytes from human prostate tumors reveal anti-tumor reactivity and potential for adoptive cell therapy.
    Yunger S; Bar El A; Zeltzer LA; Fridman E; Raviv G; Laufer M; Schachter J; Markel G; Itzhaki O; Besser MJ
    Oncoimmunology; 2019; 8(12):e1672494. PubMed ID: 31741775
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CD8+CD103+ tumor-infiltrating lymphocytes are tumor-specific tissue-resident memory T cells and a prognostic factor for survival in lung cancer patients.
    Djenidi F; Adam J; Goubar A; Durgeau A; Meurice G; de Montpréville V; Validire P; Besse B; Mami-Chouaib F
    J Immunol; 2015 Apr; 194(7):3475-86. PubMed ID: 25725111
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Minimally cultured or selected autologous tumor-infiltrating lymphocytes after a lympho-depleting chemotherapy regimen in metastatic melanoma patients.
    Besser MJ; Shapira-Frommer R; Treves AJ; Zippel D; Itzhaki O; Schallmach E; Kubi A; Shalmon B; Hardan I; Catane R; Segal E; Markel G; Apter S; Nun AB; Kuchuk I; Shimoni A; Nagler A; Schachter J
    J Immunother; 2009 May; 32(4):415-23. PubMed ID: 19342963
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.